Methylprednisolone Sodium Succinate for Injection, USP

Hazard statements (CLP)

H315, H317, H362

Code

Statements

H315

Causes skin irritation

Signal word

WARNING. GHS Class Skin Irritation. Category 2. Skin Sensitization. category 1. Reproductive toxicity. Effects on or via lactation.

Hazard statements

Causes skin irritation. May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary statements

Obtain special instructions before use. Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. IF ON SKIN: Wash with plenty of water. IF exposed or concerned: Get medical advice/attention. Specific treatment (see ... on this label). If skin irritation occurs: Get medical advice/attention. If skin irritation or rash occurs: Get medical advice/attention. Take off contaminated clothing and wash it before reuse. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.

Principle Routes of Exposure

Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential health effects

Eye Contact with eyes may cause irritation. Signs/Symptoms Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Therapeutic side effects may include: Sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalemic alkalosis, muscle weakness, steroid myopathy, loss of muscle mass, severe arthalgia, peptic ulcer with possible perforation and hemorrhage, pancreatitis, abdominal distention, impaired wound healing, thin fragile skin, petechiae and ecchymosis, increased cranial pressure with papilledema (usually after treatment, convulsions, vertigo, development of Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness, posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos, negative nitrogen balance due to protein catabolism, anaphylactic reaction, hyper/hypopigmentation, subcutaneous and cutaneous atrophy, sterile abscess, urticaria, nausea and vomiting, cardiac arrhythmias, hypotension, or hypertension. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Overexposure to corticosteroids may increase susceptibility to infection including reactivation of latent Conditions tuberculosis and enhancement of secondary eye infection due to fungi or viruses, or mask some signs of infection. Recent immunization procedures may result in a lack of antibody response and neurological disorders. Hypersensitivity to this material may result. Corticosteroids exhibit enhanced effects on persons with hypothyroidism or cirrhosis.